Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers

Trial Profile

Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B; HIV infections
  • Focus Pharmacokinetics
  • Acronyms HPTN066
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Nov 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top